Rise Therapeutics Receives FDA IND Clearance to Initiate Clinical Testing of R-5780 in Cancer
ROCKVILLE, Md., Jan. 13, 2025 /PRNewswire/ -- Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted